IL6 and Methicillin-Resistant Staphylococcus Aureus Pneumonia: These findings suggest that both JAK inhibition via baricitinib and IL‐6 deletion do not enhance host defense or limit tissue injury in murine models of influenza and post‐influenza MRSA pneumonia.